Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $27.7 million.

  • Inmune Bio's Cash & Equivalents fell 1734.02% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 1734.02%. This contributed to the annual value of $20.9 million for FY2024, which is 4163.69% down from last year.
  • According to the latest figures from Q3 2025, Inmune Bio's Cash & Equivalents is $27.7 million, which was down 1734.02% from $33.4 million recorded in Q2 2025.
  • In the past 5 years, Inmune Bio's Cash & Equivalents ranged from a high of $84.5 million in Q3 2021 and a low of $19.3 million during Q1 2025
  • In the last 5 years, Inmune Bio's Cash & Equivalents had a median value of $41.8 million in 2023 and averaged $44.7 million.
  • As far as peak fluctuations go, Inmune Bio's Cash & Equivalents soared by 72059.8% in 2021, and later plummeted by 4901.87% in 2024.
  • Inmune Bio's Cash & Equivalents (Quarter) stood at $74.8 million in 2021, then tumbled by 30.29% to $52.2 million in 2022, then plummeted by 31.26% to $35.8 million in 2023, then plummeted by 41.64% to $20.9 million in 2024, then skyrocketed by 32.56% to $27.7 million in 2025.
  • Its Cash & Equivalents stands at $27.7 million for Q3 2025, versus $33.4 million for Q2 2025 and $19.3 million for Q1 2025.